Abstract Background: Recurrent in-stent restenosis (ISR) refractory to repeated percutaneous interventions remains a formidable clinical challenge. Despite the established efficacy of drug-coated balloons (DCBs) and drug-eluting stents, a subset of patients experience relentless restenosis, highlighting the need for novel systemic strategies targeting underlying pathophysiological drivers.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Tianshu
Contact Tianshu, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack